LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Serum Vimentin Predicts Mortality in Pediatric Severe Sepsis

By LabMedica International staff writers
Posted on 14 Jun 2022
Image: The Human P-Selectin ELISA Kit – serum vimentin levels were positively correlated with P-selectin in pediatric severe sepsis (Photo courtesy of MULTI SCIENCES(LIANKE) BIOTECH, CO.,LTD).
Image: The Human P-Selectin ELISA Kit – serum vimentin levels were positively correlated with P-selectin in pediatric severe sepsis (Photo courtesy of MULTI SCIENCES(LIANKE) BIOTECH, CO.,LTD).

Sepsis is defined as a life-threatening organ dysfunction caused by a dysregulated host response to infection. It is a leading cause of death worldwide in the pediatric population. Vascular hyperpermeability by loss of endothelial barrier integrity is a hallmark of sepsis.

Inflammatory response during sepsis triggers endothelial barrier dysfunction, consequently resulting in not just vascular leak and edema, but even shock and organ failure. The cytoskeletal filament vimentin is inherent to the endothelial phenotype and is critical for the proper function of endothelial cells. The association between serum vimentin and the prognosis of sepsis in children remains indeterminate.

Critical Care doctors at the Shanghai Children's Hospital (Shanghai, China) conducted a prospective study of pediatric severe sepsis (PSS) cases who were admitted to the pediatric intensive care unit (PICU) from January 2018 to December 2020. A total of 108 patients with PSS with a median age of 19.5 month were enrolled.

The laboratory indexes included routine blood indexes (white blood cell, platelet, C-reactive protein, lactate dehydrogenase, lactic acid [Lac]), cytokines (interleukin [IL]-6, IL-10, tumor necrosis factor-α), immune indexes (NK%, CD4+ CD8+, CD19), biomarkers of endothelial cell injury (serum intercellular adhesion molecule, serum vascular cell adhesion molecule, P-selectin).

For the serum vimentin assay, serum was collected within six hours of PICU admission and stored at –80 °C. Serum vimentin levels were determined using enzyme-linked immunosorbent assays: Human Vimentin ELISA Kit (MultiScience, LIANKE Biotech, CO., LTD, Hangzhou, China) with the range of 0.2–60 ng/mL. ELISA was performed in duplicate, and other assays were performed in strict accordance with the manufacturers’ instructions.

The scientists reported that the hospital mortality rate was 19.44% (21/108). Comparing with healthy controls, serum vimentin levels on PICU admission were significantly higher in patients with PSS. The area under the ROC curve for vimentin to predict the hospital mortality was 0.712 (95% CI: 0.578–846) with a sensitivity of 71.4% and a specificity of 70.1%. Moreover, hospital mortality was significantly higher in patients with vimentin level over the cutoff value of 24.53 ng/mL than in patients with vimentin level below 24.53 ng/L.

Serum levels of sICAM-1, sVCAM-1 and P-selectin displayed an increased tendency in non-survivors compared with survivors. NK (%) was significantly lower in non-survivors than in survivors (2.94 versus 4.34), whereas serum Lac levels at PICU admission displayed higher tendency in non-survivors (2.6 mmol/L versus 2.1 mmol/L). According to the results of correlation analysis, serum vimentin levels were positively correlated with P-selectin and NK (%).

The authors concluded that serum vimentin level as an indicator of endothelial injury is associated with the prognosis of PSS, and serum vimentin level ≥24.53 ng/mL on PICU admission predicts high risk for hospital mortality in PSS. The study was published in the August 1 2022 issue of the International Journal of Infectious Diseases.

Related Links:
Shanghai Children's Hospital 
LIANKE Biotech 

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Hematology Consumables
Bioblood Devices

Channels

Molecular Diagnostics

view channel
Image Credit: iStock

Mpox Analysis Reveals Substantial Suspected False Positives Associated with Contamination

Reliable confirmation of mpox can be difficult where multiple rash-causing illnesses co-circulate and laboratory capacity is limited. Although PCR is central to case detection, contamination during specimen... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Ebola remains a rapidly evolving public health threat with high mortality, underscoring the need for timely diagnosis and decentralized testing closer to patients (Image Credit: Adobe Stock)

Collaboration Targets Blood-Based Ebola Detection Outside Central Laboratories

Co-Diagnostics, Inc. (Salt Lake City, UT, USA) and ReadyGo Diagnostics Ltd. (Bath, UK) have initiated a collaboration to evaluate ReadyGo’s GoCollect with the Co-Dx PCR platform for blood-based molecular... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more